Compare AbbVie Inc (ABBV) vs Plug Power Inc (PLUG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Plug Power Inc — how do they compare? AbbVie Inc trades at $254.16 (market cap $449.91B), while Plug Power Inc trades at $2.46 (market cap $3.46B). The key difference: AbbVie Inc is far larger — about 130× Plug Power Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| ABBV | PLUG | |
|---|---|---|
Market Cap | $449.91B | $3.46B |
Sector | Health | Industrials |
52-Week High | $261.07 | $4.14 |
52-Week Low | $184.85 | $1.40 |
Enterprise Value | $513.38B | $4.25B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Plug Power (PLUG) trades at $2.48, down 6.06% today amid sector-wide profit-taking, despite recent operational milestones. The stock shows a bearish technical signal with key resistance at $3.00. Fundamentally, the company reported a net loss of $1.63 billion in 2025 with negative gross and net margins, though it has beaten EPS estimates for three consecutive quarters. Revenue grew to $709.92 million in 2025 from $629 million in 2024, but cash flow remains negative, requiring financing to cover operations.
The outlook is high-risk with a path to profitability projected by 2028, but consistent losses and high cash burn pose significant challenges. Analyst consensus is mixed with a $3.28 price target, offering potential upside, yet investors face substantial execution and funding risks. The stock's viability hinges on successful scaling of hydrogen projects and achieving positive cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →
